Catalyst
Slingshot members are tracking this event:
Rigel (RIGL) Expects Full Results from Phase 2 Study of Fostamatinib in IgA Nephropathy in 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| RIGL |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 03, 2018
Occurred Source:
http://ir.rigel.com/phoenix.zhtml?c=120936&p=irol-newsArticle&ID=2340730
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2, Fostamatinib, Iga Nephropathy
